Aggarwal Gaurav
SEC insider (Form 3/4/5 filer). CIK 0001551965. Director at Unicycive Therapeutics, Inc. (UNCY) and 1 other issuer. 8 reported Form 4/5 transactions since Sep 2024; latest on Aug 25, 2025. Located in LOS ALTOS, CA.
Companies Aggarwal Gaurav has filed insider reports for
- Unicycive Therapeutics, Inc. (UNCY): Director
- GERON CORP (GERN): Director
Aggarwal Gaurav
CIK: 0001551965
Transaction Breakdown
High conviction signal
Position reduction
Derivative conversions
Compensation grants
Gifts, tax withholding, conversions, dispositions to the issuer and other codes
Discretionary Trading P&L
Holdings
Transaction History (8 total)
- Aug 25, 2025UNCY
Unicycive Therapeutics, Inc.
DispositionIndirectSeries A-2 Prime Preferred Stock
3.2K shares at avg. $1000.00- - Aug 25, 2025UNCY
Unicycive Therapeutics, Inc.
ConversionIndirect652.9K shares- - Jul 28, 2025UNCY
Unicycive Therapeutics, Inc.
AwardDirectStock Options
21.2K shares- - May 21, 2025GERN
GERON CORP
AwardDirectStock Option (right to buy)
180K shares- - Feb 18, 2025UNCY
Unicycive Therapeutics, Inc.
ConversionIndirect1.4M shares- - Feb 18, 2025UNCY
Unicycive Therapeutics, Inc.
DispositionIndirectSeries A-2 Prime Preferred Stock
686 shares at avg. $1000.00- - Oct 9, 2024UNCY
Unicycive Therapeutics, Inc.
ConversionIndirect5.5M shares- - Oct 9, 2024UNCY
Unicycive Therapeutics, Inc.
DispositionIndirectSeries A-2 Prime Preferred Stock
2.7K shares at avg. $1000.00-
| Type | Shares | Price | Ownership | |||
|---|---|---|---|---|---|---|
| Aug 25, 2025 |  UNCY Unicycive Therapeutics, Inc. | Disposition Series A-2 Prime Preferred Stock | 3,199 | $1000.00 | - | Indirect |
| Aug 25, 2025 | UNCY Unicycive Therapeutics, Inc. | Conversion | 652,900 | - | - | Indirect |
| Jul 28, 2025 | UNCY Unicycive Therapeutics, Inc. | Award Stock Options | 21,200 | - | - | Direct |
| May 21, 2025 |  GERN GERON CORP | Award Stock Option (right to buy) | 180,000 | - | - | Direct |
| Feb 18, 2025 | UNCY Unicycive Therapeutics, Inc. | Conversion | 1,400,000 | - | - | Indirect |
| Feb 18, 2025 | UNCY Unicycive Therapeutics, Inc. | Disposition Series A-2 Prime Preferred Stock | 686 | $1000.00 | - | Indirect |
| Oct 9, 2024 | UNCY Unicycive Therapeutics, Inc. | Conversion | 5,500,000 | - | $0 | Indirect |
| Oct 9, 2024 | UNCY Unicycive Therapeutics, Inc. | Disposition Series A-2 Prime Preferred Stock | 2,695 | $1000.00 | - | Indirect |
1-8 of 8 transactions